title: Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review.
abstract: There is no doubt that, along with surgery, chemoradiotherapy is an important treatment for esophageal squamous cell carcinoma (ESCC). Patients who respond well to chemoradiotherapy obtain great benefits toward overcoming their cancer, and so a more favorable prognosis. On the other hand, patients who do not respond well have wasted valuable time and experienced severe toxicity and seriously diminished quality of life, only to have their cancer recur with an unfavorable prognosis. For this reason, a reliable biomarker of chemoradiosensitivity in ESCC has long been sought. In this review, we will enumerate recently reported candidate biomarkers of chemoradiosensitivity in ESCC that have the potential for future clinical application.
authors: Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
authors: Yusuke
authors: Y
authors: Sato
authors: Satoru
authors: S
authors: Motoyama
authors: Hajime
authors: H
authors: Saito
authors: Yoshihiro
authors: Y
authors: Minamiya
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy; D004938:Esophageal Neoplasms / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D051847:Lithostathine / Q000032:analysis; D051267:NF-E2-Related Factor 2 / Q000032:analysis; D019947:Receptors, Interleukin-6 / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D051847:Lithostathine; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; C497617:REG1A protein, human; D019947:Receptors, Interleukin-6; D042461:Vascular Endothelial Growth Factor A